In this study, we examined a series of 142 GC cases, in which HER2 and MSI markers were determined and correlated with clinicopathological data to assess whether, as proposed, this could have an influence on treatment or prognosis [4,5,8,31,33]. The gene discussed is ERBB2; the disease is gastric cancer.